STUDresearch · Non-peptide
Amlexanox
Also known as
Aphthasol · CHX 3673 · TBK1 IKKε inhibitor · amlexanox oral
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Niche talk
Systemic
Oral / Mouth paste
Metabolic & longevity adjacents
Whole-body oral capsule in the fat-loss talk — not a mouth-ulcer smear.
What people say
Biohackers discuss this non-peptide TBK1/IKKε inhibitor for slow fat-loss or insulin-sensitivity effects, with mixed results. Oral metabolic use is a different product context from the old Aphthasol mouth-ulcer paste.
Doses people talk about
These rows describe source regimens, not a progression. Compounded capsules, research products and Aphthasol paste are different preparations; the paste is not a way to meet an oral milligram target.
How it may feel
Some accounts describe warmth or a gradual leaner look; others report GI effects or nothing useful. Actual inflammation/MCAS follow-ups include early sensations resolving and continued nulls—not a predictable fat-loss clock.
Low-dose chart discussion10 / 20 / 25+ mg/day
A Reddit guide's tier labels are not endorsed. Its author reported GI distress at 25+ mg and did not go higher; these are not the trial amounts.
Clinic-compound discussion40 mg once daily; BID/TID also discussed
The original walkthrough note describes frequency changes according to tolerance. That context is retained as reporting, not an instruction to escalate.
Metabolic trial context50 mg three times daily = 150 mg/day
The randomized study used oral tablets for 12 weeks. The separate pilot used 25 mg TID for 2 weeks, then 50 mg TID for 10 more—also 12 weeks total.
Half-life & effect duration
- Half-life in the body
- Mouth-ulcer pasteAbout 3.5 hours
- Swallowed tablets / capsulesNo settled estimate
- Felt duration people report
- Early experiencesSedation or a floaty feeling, sometimes fading
- Continued useWeeks of benefit claims, no further weight loss, or no change
Cycles people discuss
Community blocks of 4–8 or 8–12 weeks are discussed alongside 12-week metabolic studies. Study length does not validate either community block as a self-directed cutting cycle.
Timing
Meal-time split dosing is discussed for tolerability, and training appears in the metabolic rationale. The trial's three-times-daily schedule is not proof of a particular felt window.
Stacks
GLP-1s, berberine/metformin and LDN appear in overlapping cutting or inflammation discussions. Multi-drug accounts make benefits, GI effects and rashes hard to assign.
Watch for
Rash: Reported in the metabolic studies and sometimes transient under study supervision. That description is not a guarantee that a new rash or hypersensitivity reaction is mild or should be ignored.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A capsule-specific half-life is not established by the checked metabolic study.
The 3.5-hour figure comes from 100 mg of 5% mouth-ulcer paste (5 mg active), not a swallowed 25/50 mg tablet. Twelve-week serum measurements do not determine elimination half-life.
Paste absorption and compounded release formulations cannot be substituted for tablet PK. No TID regimen or felt duration is inferred from the paste number.
- Oral amlexanox — pilot and randomized metabolic studies (opens in a new tab)Actual full article HTML via ?report=xml: Results 'Amlexanox improves metabolic parameters...' / randomized study / responder analysis and drug-level paragraph, plus tablet protocol. Pilot: 6 adults, 25 mg TID two weeks then 50 mg TID ten weeks. RCT: 42 randomized, 50 mg TID twelve weeks.Obese adults with T2D/NAFLD receiving other stable therapy. RCT weight difference was not significant; responder classification used HbA1c, not a permanent personal label. Twelve-week serum levels are not a half-life study. Rash observations do not guarantee mild or transient reactions for everyone.
- 5% amlexanox oral paste — pharmacokinetics (opens in a new tab)Original abstract via Europe PMC core API: after 100 mg of 5% paste (5 mg active), serum peak 120 ng/mL at 2.4 h and elimination half-life 3.5 h.Aphthasol oral-mucosal paste, with systemic absorption thought mainly gastrointestinal. Not swallowed 25/50 mg tablets, compounded IR/slow-release capsules or a fat-loss dose. The paste is not a substitute for those products.
Felt duration people report
Accounts vary from early sensations to weeks of benefit claims or no change.
Visible follow-ups include resolution of a floaty feeling without further weight loss, ongoing benefit reports and a null poster who reconsidered the initial sedation attribution.
Different illnesses, doses, formulations and other medicines; the 3–5-week leaning talk is not a measured per-dose duration or proven fat loss.
- Amlexanox experiences with follow-ups (opens in a new tab)Actual amahutchins March 23, 2025 day-five floaty feeling/early weight-change post and April 2 resolution/no further weight-loss reply; xbt_ two-week null and later stopped-after-weeks reply; Inevitable_Guava8906 March 9 benefit and June 15 continuing-benefit reply.MCAS/inflammation accounts, not matched metabolic-trial patients or verified fat-loss outcomes. Multiple drugs and unspecified dose/route in some replies. Early weight change is not established fat loss and symptoms do not define drug residence.
- Amlexanox update — null outcome and corrected attribution (opens in a new tab)Actual under_the_sunz June 26, 2026 OP and later replies: initially blamed morning sedation; then stopped/restarted without change and questioned that attribution; latest visible reply still 40 mg twice daily with no noticeable result.Same-author follow-up retracts the initial confident sedation link. Other medicines include progesterone and LDN. Unverified individual null experience; not evidence that all non-responders remain so.
- Amlexanox low-dose chart with a personal GI report (opens in a new tab)Actual March 2025 post, Dosing/How To Use and Side Effects: 10, 20 and 25+ mg/day chart; author reports GI distress at 25+ and not going further; food and appetite statements.Commercially framed guide with one personal adverse-effect claim, not independent efficacy research or a safe progression. No verified later use follow-up was visible. Mechanism and generalized safety claims are not adopted.
What people say
- Responder talk: Hunter-Williams-style recap: people with hotter adipose inflammation may be the ones who notice. Phenotype, not a guarantee. forum
- Forum lean: 3–5 week “clothes slightly looser / midsection” logs on stable calories; a chunk feel nothing. anecdote
- Warmer training: Some mention baseline heat or extra sweat. Easy to confound with caffeine or a cut. anecdote
- Appetite comparison: Community discussion contrasts amlexanox with tirzepatide-style appetite suppression, but that does not establish that it cannot affect appetite; the low-dose guide itself lists reduced hunger among reports. forum
- Insulin resistance (small human program): Proof-of-concept obese T2D / NAFLD work — mixed glucose numbers, better insulin-resistance readouts in most of a tiny first group; later placebo-controlled slice at 50 mg TID. trial
- Liver fat: Same program’s NAFLD angle; not a resmetirom-class outcome trial. trial
- Weight: Human change is modest/variable in the small pilot; the later placebo-controlled study found no significant between-group weight-loss difference, including in the glucose-responder subgroup. Mice supplied the dramatic before/after story. trial
Doses people talk about
- Gray-market low: A Reddit guide labels 10 mg/day “beginner,” 20 mg/day “intermediate” and 25+ mg/day “advanced,” with the author reporting GI distress at 25+ and not going further. These are the guide's labels, not an endorsed ladder, and differ sharply from the metabolic study amounts. forum
- Clinic-compound talk: The original note attributes 40 mg once daily and BID/TID tolerance discussion to YouTube clinician walkthroughs; that attribution is not independently checked here. A separate inspected account reported no noticeable benefit at 40 mg twice daily. Neither account is an instruction to increase frequency. forum
- With meals: Nausea hedge. forum
- Cycle talk: 8–12 week blocks then reassess labs. forum
- Don’t swallow Aphthasol paste for a milligram target. Different product. forum
- Hunter recap of the Phase 2 number: 50 mg TID = 150 mg/day. forum
- Framing: Trial milligrams vs gray-market “research caps” — not a prescription for you. forum
- Metabolic study regimens: The six-person open-label pilot used 25 mg three times daily (75 mg/day) for two weeks, then 50 mg three times daily (150 mg/day) for ten more weeks: 12 weeks total, not 10–12 extra weeks. The separate randomized study used 50 mg TID for 12 weeks. trial
How it may feel
- Days 1–7: GI effects or no obvious change are discussed, not a predictable stimulant kick. One inflammation/MCAS poster described a floaty day-five feeling and early weight change, then reported that the feeling resolved and weight loss did not continue. forum
- Weeks 3–5: Forum “maybe leaning” checkpoint. anecdote
- Non-response and escalation: Some people report no useful change. A 40 mg twice-daily MCAS poster later still reported nothing noticeable and retracted the initial attribution of morning sedation after stopping/restarting did not change it. That does not establish permanent non-response. Moving from gray 10 mg caps toward 150 mg/day without clinical oversight remains a GI and dose-context concern, not a solution. forum
- Weeks 2–3: In the six-person metabolic pilot, 25 mg TID was used for two weeks before 50 mg TID for ten more weeks. That transition describes a study, not when benefits should be felt or a personal progression. trial
- Weeks 8–12: A checkpoint range in discussion; the metabolic studies treated participants for 12 weeks. Labs rather than mirror impressions were the trial endpoints, not instructions for a self-directed course. trial
- Rash window: Transient rash is the AE people actually name. trial
Around the dose
- Labs people actually name: Fasting insulin/glucose, A1c, sometimes liver enzymes / lipids. forum
- Training: The “catecholamine brake” pitch is why it shows up next to cuts, not next to bed. forum
- Not a skip-protein-on-a-GLP move. forum
Cycles people discuss
- 8–12 weeks: A community block range near the human metabolic-study duration; the pilot and randomized treatment periods were 12 weeks. It is not a validated fat-loss cycle. forumtrial
- Then labs, not an open-ended cut drug. forum
- Gray 4–8-week “research” blocks: Lower 10–25 mg/day charts discussed here sit below the trial's 150 mg/day and 12-week period. That comparison does not make every gray-market regimen lower-dose or safer. forum
Timing
- With meals: Split doses. forum
- Not a 20-minute thermogenic. forum
- cAMP / catecholamine-sensitivity story: Mechanism talk for why it’s stacked with training, not a clen replacement. forum
- TID is a study regimen, not a measured coverage claim: The metabolic studies used oral tablets, but their 12-week serum measurements did not establish an elimination half-life. A separate 5% Aphthasol paste study reported 3.5 hours after 100 mg of paste (5 mg active); that is not a swallowed-tablet or compounded-capsule estimate. trial
More on what it is
- Why people talk: Saltiel-lab mouse work (high-fat-diet mice dropped weight without eating less) plus a small human metabolic program. Hunter Williams and cutting-stack lists keep the name warm. forum
- Not a stim: Forums describe a slow lean over weeks, maybe warmer training, not clen jitter. forum
- Dose fight: Gray-market 10–25 mg/day vs the metabolic trial’s 50 mg three times a day (150 mg/day). Those are different worlds. forum
- Not: Not a GLP-1, not DNP, not the canker gel swallowed as a fat-loss hack. forum
- What it is: Old small molecule. US canker-sore paste was Aphthasol. Biohackers pulled it for TBK1 / IKKε — kinases that sit high in inflamed fat. Not a peptide. trial
- Mouse vs human gap: Mice: obvious fat loss. Humans: more “A1c / liver fat / insulin sensitivity in responders,” tiny scale weight. trial
Stacks
- GLP-1s: Multi-pathway cut lists. Confounded as hell. forum
- ATX-304 / SLU-PP-332 / BAM15: Neighbor metabolic research names. forum
- Berberine / metformin: Insulin-sensitivity aisle. forum
- LDN: Occasional inflammation-crossover talk. forum
- Don’t stack with mystery thermogenics and then blame the rash. forum
Storage notes
- Capsules: Dry bottle. Not a peptide pin. forum
- No mix instructions here: STUDresearch does not list reconstitution charts. forum
Watch for
- GI: Gray-market logs at even 25 mg/day. forum
- Hypersensitivity: Old drug class; rare allergy talk. forum
- Glucose meds: If someone is already on insulin or sulfonylureas, stacking insulin-sensitizer talk is a hypoglycemia caution, not a hack. forum
- Liver / diabetes workups: NAFLD curiosity is not a reason to skip real hepatology. forum
- Gray vs compounded vs paste: Three different products. forum
- Rash: Reported in the metabolic studies and sometimes transient under study supervision. That description is not a guarantee that a new rash or hypersensitivity reaction is mild or should be ignored. trial
- Not FDA-approved as a weight-loss drug. Aphthasol was the ulcer paste. trial
- Research-only framing: Discussion of community practice — not a recommendation to use in humans or animals. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.